GGrantIndex
← Search

CORE--TRANSGENIC MOUSE

$0P30FY2002CANIH

Yeshiva University, New York NY

Investigators

Linked publications, trials & patents

Paper 39499645Paper 39392861Paper 39378878Paper 39332920Paper 39259591Paper 39207105Paper 39193906Paper 39127153Paper 39081315Paper 39028768Paper 39025270Paper 38902475Paper 38898085Paper 38896451Paper 38863869Paper 38778498Paper 38753503Paper 38717519Paper 38700353Paper 38699331Paper 38679747Paper 38657656Paper 38645169Paper 38643166Paper 38608634Paper 38597673Paper 38571760Paper 38565851Paper 38559037Paper 38477945Paper 38463959Paper 38458178Paper 38436133Paper 38405931Paper 38402617Paper 38400039Paper 38387080Paper 38352476Paper 38334805Trial NCT05016622Trial NCT04514484Trial NCT04401670Trial NCT03648983Trial NCT02774291Trial NCT02649569Trial NCT02578888Trial NCT02575872Trial NCT02527304Trial NCT02507076Trial NCT02382419Trial NCT02277561Trial NCT02112552Trial NCT02073968Trial NCT02038153Trial NCT02009436Trial NCT01958580Trial NCT01939210Trial NCT01899326Trial NCT01899261Trial NCT01897454Trial NCT01897441Trial NCT01857271Trial NCT01772420Trial NCT01697293Trial NCT01695941Trial NCT01605032Trial NCT01408160Trial NCT01367301Trial NCT01351909Trial NCT01319539Trial NCT01231906Trial NCT01145430Trial NCT01142401Trial NCT01061606Trial NCT01041027Trial NCT01001910Trial NCT00950365Trial NCT00470301Trial NCT00450944Trial NCT00437034Trial NCT00392353Trial NCT00324740Trial NCT00182767Trial NCT00179348Trial NCT00121251Trial NCT00096317Trial NCT00066638Trial NCT00057863Trial NCT00055692Trial NCT00030706Trial NCT00019474Trial NCT00004864Trial NCT00004863Trial NCT00003867Trial NCT00002461Patent 9671391Patent 7709613Patent 6821725Patent 6013468Patent 5876979

Abstract

DESCRIPTION (provided by applicant): The Transgenic Shared Resource trains and assists AECCC investigators in the production and characterization of transgenic mice through introduction of DNA sequences into the germline, usually by microinjection into the pronuclei of fertilized oocytes. This facility provides advice on transgene constructs, preparation of DNA in a form suitable for successful injection, micro-injection of oocytes, transfer to pseudo-pregnant recipients, and care of pups to weaning at which time mice are returned to investigators for analysis. To support these services, a core colony of mice is maintained to generate pseudopregnant females, superovulated mice for oocyte retrieval, vasectomized males, etc. The facility provides rigorous testing of pre-implantation culture medium, anesthetics for mice, hormones for super-ovulation, and reagents for DNA purification. In addition, colony rederivation is provided for pathogen-infected mice, in vitro fertilization to rescue colonies that are having difficulty breeding and transient transgene analysis for lethal genes. The facility has extensive microinjection stations maintained and operated by a highly experienced staff with long-standing experience in generating transgenic mice. At least three founders are guaranteed per construct injected although the number is usually greater. There has been essentially a 100% success rate in generating transgenic mice with minimal re-injection necessary. Between 15-20 principal investigators use the facility each year and many have multiple constructs injected. Investigators with little-or-no experience in mouse biology are trained in relevant methodologies as well as more general aspects of mouse genetics, reproduction, husbandry, and mammalian developmental biology. Investigators who plan to use transgenic mice extensively often take the yearly course in "Mouse Developmental Genetics" sponsored by the facility. This has propagated a large cadre of investigators and trainees at AECCC skilled in transgenic methodologies. Dr. Jeffrey Pollard replaced Dr. Ron DePinho as faculty supervisor in 1998 and has implemented several changes. Stringent quality-control procedures were adapted and all DNA to be injected is now purified by the transgenic facility staff. The FVB strain of mice has become the preferred recipient for transgenes because of its relative ease of injection and the inbred nature of the strain. In addition, the facility has been successful at establishing transgenic mice using BAC DNA. Mice generated in this facility were the first to show that the tetracycline-regulated system is operable in vivo. More recently, the facility has aided in the generation of mice in which tissue regulation is effected through the ecdysone-regulatory system. Advice and assistance on the use of these systems are available to all AECCC.

View original record on NIH RePORTER →